Eli Lilly and CoXSWX:LLY +4.37%100 Shareholder Yield % is 0.19% as of Mar. 2026, which is 86% below its 10-year median of 1.36. GuruFocus rates XSWX:LLY with a GF Score™ of 100/100 and a GF Value™ of CHF1,114.27 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 972 Drug Manufacturers companies, Eli Lilly and Co ranks worse than 51.23% on this metric.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return.
As of today, Eli Lilly and Co's Shareholder Yield % was 0.19%.
Eli Lilly and Co (XSWX:LLY) Shareholder Yield % Explanation
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."
Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.
Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.
Eli Lilly and Co Shareholder Yield % Related Terms
Eli Lilly and Co Shareholder Yield % Historical Data
* Premium members only.
The historical data trend for Eli Lilly and Co's Shareholder Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:LLY vs JNJ, ABBV, MRK: Shareholder Yield % Comparison
For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eli Lilly and Co Shareholder Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Shareholder Yield % distribution charts can be found below:
* The bar in red indicates where Eli Lilly and Co's Shareholder Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
Eli Lilly and Co (XSWX:LLY) has a Shareholder Yield % of 0.19% as of Mar. 2026. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Eli Lilly and Co and its competitors. This is 86% below median its historical median of 1.36. According to the industry distribution chart, Eli Lilly and Co ranks #498 out of 972 companies in the Drug Manufacturers industry, placing it in the top 51.2%.
Is Eli Lilly and Co's Shareholder Yield % too high?
Eli Lilly and Co's current Shareholder Yield % of 0.19% is 86% below median its 10-year median of 1.36. The Drug Manufacturers industry median Shareholder Yield % is 0.30. Eli Lilly and Co's value of 0.19% is 36.7% below this industry median. Based on the distribution chart, Eli Lilly and Co ranks #498 out of 972 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Eli Lilly and Co has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eli Lilly and Co's Shareholder Yield % compare to JNJ and ABBV?
According to the Drug Manufacturers industry distribution chart, Eli Lilly and Co ranks #498 out of 972 companies for Shareholder Yield %. This places Eli Lilly and Co in the lower half of its industry. The industry median Shareholder Yield % is 0.30. Eli Lilly and Co's value of 0.19% is 36.7% below this benchmark. While the company's 10-year median is 1.36 vs. the industry median of 0.30, Eli Lilly and Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Drug Manufacturers company?
The median Shareholder Yield % among Drug Manufacturers companies is 0.30, based on 972 companies in the industry. Companies in the top quartile (top 25%) have a Shareholder Yield % significantly above this median, while those in the bottom quartile fall well below. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eli Lilly and Co's current Shareholder Yield % of 0.19% is 36.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Eli Lilly and Co and its competitors. For the Drug Manufacturers industry, the median Shareholder Yield % is 0.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eli Lilly and Co's current Shareholder Yield % is 0.19%, which is 86% below median its own 10-year median of 1.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eli Lilly and Co stock overvalued right now?
Based on GuruFocus' analysis, Eli Lilly and Co (XSWX:LLY) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF1,114.27, compared to a current price of CHF955.00 — trading 14.3% below its estimated fair value. The current Shareholder Yield % is 0.19%, which is 86% below median its 10-year median of 1.36 and 36.7% below the Drug Manufacturers industry median of 0.30. Eli Lilly and Co's overall GF Score™ is 100/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Eli Lilly and Co (XSWX:LLY), the current Shareholder Yield % is 0.19% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eli Lilly and Co (XSWX:LLY) Overvalued in 2026?
Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued.
The current stock price of CHF955.00 is trading 14.3% below its estimated GF Value™ of CHF1,114.27.
GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.
Key valuation signals for XSWX:LLY:
Shareholder Yield %: 0.19% (86% below median its 10-year median of 1.36)
GF Value™: CHF1,114.27 vs. price of CHF955.00 (14.3% below fair value)
Industry Position: 36.7% below the Drug Manufacturers median (#498 of 972)
No single metric tells the full story. See the XSWX:LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
100GF Score
Get the complete analysis for XSWX:LLY
Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:LLY has been successfully added to your 
